VolitionRx Limited reported a total revenue of $1.73 million for the fiscal year ended December 31, 2025, marking a 40% increase from $1.23 million in 2024. The revenue growth was primarily driven by product sales, particularly from the Nu.Q® Vet Cancer Test and Nu.Q Discover kits. Despite this increase in revenue, the company continued to experience significant net losses, reporting a net loss of $23.5 million, which is a reduction from the $27.3 million loss reported in the previous year. The decrease in net loss was attributed to lower operating expenses, which fell to $23.5 million from $28.3 million in 2024.
In terms of operational developments, VolitionRx has made strides in its product offerings and market presence. The company has focused on expanding its product portfolio, which includes various blood tests aimed at early disease detection, particularly in cancer and sepsis. The Nu.Q® Vet Cancer Test is now available in over 20 countries, and the company has established partnerships with major veterinary diagnostic firms such as Antech and IDEXX. Additionally, VolitionRx has been actively pursuing regulatory approvals for its products, with plans to submit an IVDR application for its Nu.Q® NETs assay in 2026.
The company has also seen a reduction in its workforce, with full-time equivalent personnel decreasing from 85 in 2024 to 75 in 2025. This reduction was part of a strategy to prioritize cash utilization in commercial and production activities. The company’s cash and cash equivalents stood at approximately $1.1 million as of December 31, 2025, down from $3.3 million in the previous year. This decline in cash reserves raises concerns about the company's liquidity and ability to fund ongoing operations, especially given its accumulated deficit of approximately $252.9 million.
Looking ahead, VolitionRx faces challenges in achieving profitability and maintaining operations without additional capital. The company has indicated that it may need to raise further funds through equity or debt financing to support its strategic initiatives. The management has expressed a commitment to enhancing its commercialization efforts and product development, but the ongoing need for external financing raises substantial doubt about the company's ability to continue as a going concern. The company’s auditors have noted this concern in their report, emphasizing the importance of securing adequate capital to sustain operations.
In summary, while VolitionRx has shown revenue growth and made significant advancements in its product offerings, it continues to grapple with substantial losses and liquidity challenges. The company's future will largely depend on its ability to secure additional funding and successfully commercialize its diagnostic products in a competitive market.
About VOLITIONRX LTD
VolitionRx Limited is a multinational epigenetics company developing simple, cost-effective blood tests for early detection and monitoring of diseases such as cancer and sepsis in humans and animals. Its proprietary technologies analyze circulating nucleosomes and chromatin structures to enable non-invasive diagnostics, with applications spanning veterinary and human healthcare markets. The company focuses on innovative assay development, licensing IP, and strategic partnerships to improve disease management worldwide.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.